German biotech firm CureVac said its coronavirus vaccine showed just 48% efficacy against Covid-19 following its final analysis, marking only a slight improvement on the company’s last trial while sending its stock value tumbling.
CureVac announced the second- and third-phase trial results for its CVnCoV vaccine on Wednesday, in its final analysis for a 40,000-subject study that drew participants from 10 countries across Europe and Latin America.
Continue reading https://on.rt.com/bbg5